Evoke Pharma (EVOK) deregisters unsold securities following QOL Medical merger

Rhea-AI Filing Summary

Evoke Pharma, Inc. filed a post-effective amendment to several Form S-3 registration statements to deregister all securities that were previously registered but remain unsold or otherwise unissued. This action follows the completion of a merger on December 17, 2025, under which QOL-EOS Merger Sub, Inc. merged with and into Evoke Pharma, with Evoke Pharma surviving as a wholly owned subsidiary of QOL Medical, LLC.

Because of this merger, Evoke Pharma has terminated all offerings and sales of its securities under these registration statements and is formally removing any remaining unsold securities from registration, as it had previously undertaken to do. The filing notes that additional details about the merger and the Merger Agreement are available in an Exhibit to a Form 8-K filed on November 4, 2025.

As filed with the Securities and Exchange Commission on December 17, 2025

Registration No. 333-200176

Registration No. 333-221556

Registration No. 333-251614

Registration No. 333-281527

Registration No. 333-281840

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM S-3

POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-200176

POST-EFFECTIVE AMENDMENT NO. 2 TO REGISTRATION STATEMENT NO. 333-221556

POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-251614

POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-281527

POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-281840

UNDER

THE SECURITIES ACT OF 1933

EVOKE PHARMA INC.

(Exact name of registrant as specified in its charter)

Delaware		20-8447886
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification Number)

420 Stevens Avenue, Suite 230

Solana Beach, California 92075

(858) 345-1494

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Matthew Wotiz

Secretary

Evoke Pharma, Inc.

420 Stevens Avenue, Suite 230

Solana Beach, California 92075

(858) 345-1494

(Name, address, including zip code, and telephone number, including area code, of agent for service)

With copies to:

John C. Connery Jr.

Roland S. Chase

Hill Ward Henderson

101 E. Kennedy Blvd., Suite 3700

Tampa, Florida 33602

(813) 221-3900

Approximate date of commencement of proposed sale to the public: Not applicable. Removal from registration of securities that were not sold pursuant to the above referenced registration statements.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

Large accelerated filer		☐		Accelerated filer		☐
Non-accelerated filer		☒		Smaller reporting company		☒
				Emerging growth company		☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

DEREGISTRATION OF SECURITIES

This Post-Effective Amendment (this “Post-Effective Amendment”) relates to each of the following registration statements on Form S-3 (each, a “Registration Statement” and collectively, the “Registration Statements”) filed with the Securities and Exchange Commission (the “SEC”) by Evoke Pharma, Inc., a Delaware corporation (the “Registrant”):

• Registration Statement No.  333-200176, filed with the SEC on November 13, 2014;

• Registration Statement No.  333-221556, filed with the SEC on November 14, 2017, as amended on December 12, 2017;

• Registration Statement No.  333-251614, filed with the SEC on December 22, 2020;

• Registration Statement No.  333-281527, filed with the SEC on August 13, 2024; and

• Registration Statement No.  333-281840, filed with the SEC on August 29, 2024.

The Registrant is filing this Post-Effective Amendment to the Registration Statements to deregister all securities that remain unsold under the Registration Statements.

On December 17, 2025, pursuant to the terms of an Agreement and Plan of Merger, dated as of November 3, 2025 (the “Merger Agreement”), by and among the Registrant, QOL Medical, LLC, a Delaware limited liability company (“Parent”), and QOL-EOS Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), Merger Sub merged with and into the Registrant, with the Registrant surviving the merger as a wholly owned subsidiary of Parent (the “Merger”).

As a result of the Merger, the Registrant has terminated any and all offerings and sales of its securities pursuant to the Registration Statements. In accordance with undertakings made by the Registrant in each Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statements that remain unissued at the termination of the offerings, the Registrant hereby files this Post-Effective Amendment to deregister all securities registered but unsold or otherwise unissued under each Registration Statement, if any, as of the date hereof.

The foregoing description of the Merger, the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the Merger Agreement, which is attached as Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on November 4, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Vero Beach, State of Florida on December 17, 2025.

Evoke Pharma, Inc.

/s/ Matthew Wotiz

Matthew Wotiz

Secretary

No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933, as amended.

FAQ

What does Evoke Pharma (EVOK) disclose in this post-effective amendment?

Evoke Pharma, Inc. uses this post-effective amendment to remove from registration all securities that remain unsold or otherwise unissued under several previously filed Form S-3 registration statements. The company states that all offerings and sales under these statements have been terminated.

Why is Evoke Pharma (EVOK) deregistering previously registered securities?

Evoke Pharma explains that, as a result of a merger completed on December 17, 2025, it has terminated any and all offerings and sales of its securities under the referenced registration statements. In line with its prior undertakings in those registrations, it is now deregistering all securities that remain unsold or unissued.

What merger transaction involving Evoke Pharma (EVOK) is described?

The filing states that on December 17, 2025, QOL-EOS Merger Sub, Inc. merged with and into Evoke Pharma, Inc. under an Agreement and Plan of Merger dated November 3, 2025. Evoke Pharma survived the merger and became a wholly owned subsidiary of QOL Medical, LLC.

How does the merger affect Evoke Pharma’s outstanding registration statements?

Because of the merger, Evoke Pharma has ended all offerings and sales of its securities under the affected Form S-3 registration statements. The company is therefore filing this post-effective amendment to deregister any securities that were registered under those statements but remain unsold or otherwise unissued as of the filing date.

Where can investors find the full terms of Evoke Pharma’s merger agreement?

The filing notes that the description of the merger and Merger Agreement is qualified in its entirety by the actual Merger Agreement, which is attached as Exhibit 2.1 to Evoke Pharma’s Current Report on Form 8-K filed with the SEC on November 4, 2025.

Who signed the Evoke Pharma (EVOK) post-effective amendment?

The post-effective amendment was signed on behalf of Evoke Pharma, Inc. by Matthew Wotiz, who is identified as the company’s Secretary. The signature indicates it was executed in Vero Beach, Florida on December 17, 2025.